Pregabalin is a new anticonvulsant therapy which holds promise as a safe and effective adjunct drug for seizure control in epileptic dogs that respond poorly to standard drugs such as phenobarbital or potassium bromide.
It is considered a next generation gabapentin which acts to reduce calcium influx and release of glutamate, an excitatory neurotransmitter.
At doses of 3 - 4 mg/kg orally every 8 - 12 hours it appears to have few side effects and is effective in idiopathic epilepsy. Sedation is the most common side effect.
- Salazar V et al (2009) Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. Vet Anaesth Analg 36(6):574-580
- Plessas IN et al (2012) Long-term outcome of Cavalier King Charles spaniel dogs with clinical signs associated with Chiari-like malformation and syringomyelia. Vet Rec 171(20):501
- Smith-Bailey, K & Dewey, CW (2010) Novel anticonvulsant therapies. In August, JR (Ed): Consultations in feline internal medicine. Vol 6. Elsevier Saunders, Philadelphia. pp:540
- Dewey CW et al (2009) Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. J Am Vet Med Assoc 235(12):1442-1449